Supplementary Figure 3

Item		Run-in period	Start of treatment	Treatment period (24 months)					
Time		Weeks u	Week 0 (For untreated group, 2 weeks after RHC)				Week 8 onwards		
				(Week 1)	Week 2	Week 4	Every 4 weeks	Every 6 months	At completion (discontinuation)
Informed consent		0							
Patient background		0							
Study drug administration (Drug to treat PAH)*			←						-
Subjective and objective symptoms		0	0	0	0	0	0	0	0
Monitoring for adverse events			-						
Blood pressure		0			o*	0	0	0	0
Pulse rate		0			o *	0	0	0	0
Body weight		0						0	0
Laboratory tests	Hematology	0			o *	o *	0	0	0
	Biochemistry (NT- proBNP, etc.)	0			O*	O*	0	0	0
	Urinalysis	0				0*	0	0	0
Chest X-ray		0				0	0	0	0
ECG			0					0	
Echocardiography		0						0	0
RHC		0						0	
ADL		0	0					0	0
Exercise stress testing		0						0	0
PFT		0						0	0
Arterial blood analysis		0						0	0

^{*}To be conducted only in patients given the study drug